Back
Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders
Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.
Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders
Episodes
All
All
Please check back later for more content.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
3
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
4
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
5